Our Comprehensive Pharmacogenomics (PGX) panel offers tailored medication recommendations based on individual genetic profiles, ensuring safer and more effective treatments. This advanced test analyzes targeted SNPs (single nucleotide polymorphisms) in 38 key genes that are integral to drug response and metabolism. By providing insights into genetic variants, this panel helps healthcare providers manage potential risks, adjust dosages, and develop personalized therapeutic plans for patients.

Genes Covered: The test covers a comprehensive range of genes associated with drug metabolism and response, including:

• Transporters and Enzymes: ABCB1, ABCG2, CYP1A2, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLC28A3, SLC47A2, SLCO1B1, UGT1A6, UGT2B15.
• Receptors and Channels: ADRA2A, ADRB2, DRD2, HTR2A, OPRM1.
• Others: ADH1B, ANKK1, APOE, C11orf65, COMT, F13A1, F2, F5, GRIK4, HLA-A, IFNL3, ITGB3, MTHFR, NOS3, RARG, TPMT, VKORC1.

This extensive panel enables precise predictions of individual responses to various medications, reducing the risk of adverse effects and improving therapeutic outcomes. By understanding your genetic profile, healthcare providers can make more informed decisions, tailor treatments, and enhance overall patient care.